In this activity, Dr. Alison Moskowitz explains the importance of determining prognostic risk when treating patients who are newly diagnosed with Hodgkin lymphoma and what tools clinicians should use.

Dr. Anas Younes discusses the immune-related toxicities clinicans should be mindful of when prescribing a new checkpoint inhibitor and what you can do to help treat these side effects.

In this activity, Dr. Matasar will explain how to evaluate a patient's response to immunotherapy in the relapse and first-line setting.

Join Dr. Matasar as he discusses how to decide if a newly diagnosed Hodgkin lymphoma patient needs to have a bone marrow biopsy as part of their initial workup.

In this activity, Dr. Matasar provides an update from the ASH 2017 Annual Meeting on immunotherapy in the treatment of Hodgkin lymphoma.

Join Dr. Ansell as he will discuss the two main issues in today's management of front-line classical Hodgkin lymphoma, including bleomycin and radiation therapy.

Join Dr. John Sweetenham as he discusses the role of brentuximab vedotin as first-line salvage therapy prior to ASCT and ongoing studies using BV in combination with other conventional regimens.

In this activity, Dr Sweetenham will discuss the current options for patients with HL who have relapsed after autologous stem cell transplantation.

Dr. Ansell discusses what future changes may lie ahead beyond current treatment options in frontline therapy, focusing on new clinical trial results with brentuximab vedotin.

Join Dr. John Sweetenham as he discusses the risk factors that may predict ASCT outcomes including, primary refractory disease and extranodal disease.